The Daiichi Sankyo Group is promoting partnership-based drug discovery to make the best use of its accumulated scientific findings and global network. Partnerships bring synergies to initiatives that cannot be completed by the Group alone. This initiative contributes to Goal 17: “Partnerships for the Goals” of the Sustainable Development Goals (SDGs) adopted by the United Nations member states.
The Daiichi Sankyo Group has funded the Global Health Innovative Technology Fund (hereinafter referred to as the “GHIT Fund”) since its establishment in April 2013. To promote the development of drugs for combating infectious diseases in developing countries, the GHIT Fund was established as a public-private partnership originating in Japan and was supported by the government of Japan, five Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation. We have continued the funding for the third phase starting in April 2023 as in the first and second phases. The GHIT Fund has contributed to breakthroughs in many innovative product developments through its investments.
The Group is utilizing partnerships through the GHIT Fund structure and integrating the accumulated drug discovery capabilities, the partners' expertise in diseases, and the GHIT Fund's investment capabilities and the global network to undertake a number of projects, including one to explore the treatment of Chagas disease, which is considered to be a neglected tropical disease (NTD), and another to explore candidate anti-tuberculosis drugs made from natural products.
Daiichi Sankyo will continue with activities that contribute to fulfilling its purpose “to contribute to the enrichment of quality of life around the world,” through initiatives to create innovative pharmaceuticals and improve medical access in developing countries.

The Global Health Innovative Technology Fund

Public Sector

Private Sector

Civil Sector

The Global Health Innovative Technology Fund